Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) Return on Equity (2016 - 2025)

Lipocine (LPCN) has disclosed Return on Equity for 13 consecutive years, with 0.35% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Equity fell 15.0% year-over-year to 0.35%, compared with a TTM value of 0.35% through Sep 2025, down 15.0%, and an annual FY2024 reading of 0.0%, up 58.0% over the prior year.
  • Return on Equity was 0.35% for Q3 2025 at Lipocine, down from 0.25% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.11% in Q3 2022 and bottomed at 0.76% in Q4 2023.
  • Average Return on Equity over 5 years is 0.3%, with a median of 0.33% recorded in 2023.
  • The sharpest move saw Return on Equity surged 178bps in 2021, then tumbled -74bps in 2023.
  • Year by year, Return on Equity stood at 0.02% in 2021, then crashed by -1714bps to 0.29% in 2022, then plummeted by -160bps to 0.76% in 2023, then surged by 100bps to 0.0% in 2024, then crashed by -84197bps to 0.35% in 2025.
  • Business Quant data shows Return on Equity for LPCN at 0.35% in Q3 2025, 0.25% in Q2 2025, and 0.27% in Q1 2025.